Celator Pharmaceuticals Inc 4
4 · Celator Pharmaceuticals Inc · Filed Jun 22, 2016
Insider Transaction Report
Form 4
Kovner Bruce
10% Owner
Transactions
- Gift
Common Stock
2016-06-21−564,222→ 1,593,676 total(indirect: By LLC) - Gift
Common Stock
2016-06-21−1,926→ 1,591,750 total(indirect: By LLC) - Gift
Common Stock
2016-06-21+564,222→ 564,222 total(indirect: See Footnote) - Gift
Common Stock
2016-06-21−88,571→ 2,157,898 total(indirect: By LLC)
Footnotes (3)
- [F1]This transaction represents a gift/charitable donation effective June 21, 2016. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.
- [F2]These securities are owned directly by CDK Associates, LLC, which is a reporting person. The securities directly owned by CDK Associates, LLC may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each of Caxton Corporation and Bruce Kovner disclaims beneficial ownership of these securities except to the extent of its or his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed to be an admission of the beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
- [F3]These securities are owned directly by an investment entity wholly-owned by Bruce Kovner's family's charitable foundation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of the investment entity wholly-owned by the foundation, and (ii) Bruce Kovner, the co-chairman of the foundation and the chairman and sole shareholder of Caxton Corporation. Each of Caxton Corporation and Bruce Kovner disclaims beneficial ownership of these securities except to the extent of its or his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed to be an admission of the beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.